Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — B&K Securities Annual Investor Conference 2024
30 slides from Natco Pharma's conference presentation, May 29, 2024
Slide 1: Cover letter to stock exchanges: Investor Presentation
29th May, 2024 The Manager - CRD The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra Kurla Complex, Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Investor Presentation P
Slide 2: Natco Pharma Limited Investor Presentation May 2024
Natco Pharma Limited Investor Presentation May 2024
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Table of Contents
Table of Contents Company Overview Business Highlights Financial Overview Annexure Natco Pharma Limited – Investor Presentation – May 2024
Slide 5: Company Overview
> ov d © > O > Ss o Q £ ro} U
Slide 6: NATCO in a glance
NATCO in a glance $500 million 10 50+ Amongst top 10 generic Global revenue – FY24^ company by sales in Export to countries globally Canada* 9 450+ 4,800+ State-of-the-art manufacturing facilities – Erudite scientists and Strong and motivated Pharma & CHS (API & experienced researchers workforce glo
Slide 7: Evolved to be a diversified player across geographies
Evolved to be a diversified player across geographies 2021: Acquires Dash 2003: Launched Oncology 2012: Compulsory License 2017: Started cardiology Pharmaceuticals LLC 1981: Incorporated division with introduction of was granted by Government and diabetology divisions for NATCO Pharma Division of fl
Slide 8: Strong operational delivery over the past decade
Strong operational delivery over the past decade Revenue (INR Mn) EBITDA (INR Mn) PAT (INR Mn) Profitability (%) CAGR 17% CAGR 24% CAGR 26% 45.5% 33.6% 18,795 13,883 41,269 25.4% 16.0% 8,401 2,130 1,344 EBITDA Margin PAT Margin FY15 FY24 FY15 FY24 FY15 FY24 FY15 FY24 Business Mix ROCE and ROE (%) Em
Slide 9: Core Strengths
Core Strengths State-of-the-art and regulatory Strong R&D Capabilities compliant manufacturing capacities Capitalizing on Bringing niche products at the Strengths Experienced Management Team affordable prices Long-standing partnerships globally 8 NATCO Pharma Limited – Investor Presentation – May 20
Slide 10: Business Highlights
Business Highlights
Slide 11: Key Business Segments – FY24
Key Business Segments – FY24 Crop Health Sciences – INR 1,083 Mn >> Targeting two categories of products – bioproducts and pesticides Domestic Formulations – INR 3,867 Mn >>Successfully launched broad-spectrum insecticide >> 25 Brands^ in #1 position in indicated prescription Chlorantraniliprole (CT
Slide 12: US Market – Focus on Complex and Limited Competition Products
US Market – Focus on Complex and Limited Competition Products Key products in the portfolio* Focus on high entry barrier products that are typically characterized by one or more of the following: Therapeutic >> Intricate chemistry Brand Molecule Segment/Primary Indication >> Challenging delivery sys
Slide 13: Key Product Pipeline - USA
Key Product Pipeline - USA 24 Para IVs in the pipeline 15 Approved (either tentative or fully) Key Solo FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic Therapeutic Key Brand Molecule Key Brand Molecule Segment / Primary Indication Segment / Prim
Slide 14: Resilient Domestic Pharma Business
Resilient Domestic Pharma Business Four key business segments 4 Diabetology (Reach) 1 Oncology Focused division to increase market penetration in the diabetes market One of the pioneers in the branded oncology medicines in India. Among the top 3 companies in the Fortified anti-diabetic portfolio by
Slide 15: Expanding RoW Presence
Expanding RoW Presence >> Strong portfolio with 30+ products including Oncology, Anti-viral, Cardiovascular and CNS therapies Sales INR Mn >> Amongst top 10 generic companies by sales revenue in Canada >> Highest market share for Lenalidomide and Oseltamivir >> Launched Pomalidomide, Apixaban, Terif
Slide 16: Strategic API Business to Aid Formulations Growth
Strategic API Business to Aid Formulations Growth Strategically important business – develops APIs primarily for third party sales and also Sales INR Mn for captive consumption Portfolio of 45* active US DMFs with niche products under development Focus on complex oncology molecules. Other therapeuti
Slide 17: Manufacturing Presence & Capabilities
Manufacturing Presence & Capabilities API FDF Mekaguda, Telangana Dehradun, UTTARAKHAND Tablets, Capsules Active Pharmaceutical Ingredients and API Approved by USFDA, ANVISA, intermediaries Health Canada Approved by USFDA, WHO Nagarjunasagar, Telangana GMP and others Oncology, antibiotics and Chenna
Slide 18: Backed by Strong R&D
Backed by Strong R&D R&D capabilities demonstrated by its complex and niche product filings in Talented Pool of 494 Scientists* formulations and API segments 22% Two research facilities with capabilities across synthetic chemistry, nano pharmaceuticals, new drug discovery and cell biology 9% Special
Slide 19: Crop Health Sciences (CHS)
Crop Health Sciences (CHS) Pharma to Farm – Extending R&D capabilities to Agro Key Products NATCO CHS is a part of NATCO Pharma Ltd CHS division was initiated in 2019 with the mission to bring innovative crop solutions to farmers at an affordable price Leveraging strong Techno-Legal expertise in Pha
Slide 20: Backed by technical and formulation manufacturing facilities
Backed by technical and formulation manufacturing facilities Expertise in formulating SC, ZC, WG, FS, GR, EC, WP type formulations Fully equipped QA and QC facility Zero Liquid Discharge (ZLD) Fully automated manufacturing and packing facility Equipped with process development lab with a pilot plant
Slide 21: Strategy Ahead
Strategy Ahead Engines of Growth Focus on complex and Scaling up of domestic Tapping into newer Scaling up of Agri limited competition business geographies/markets business molecules >> Expanding reach to >> Looking for strategic wider base of inorganic opportunities >> Analysis being done to >> Hig
Slide 22: Making a Sustainable Impact
Making a Sustainable Impact 18,426 tCO2 22.3% recycled water 6 MW Solar Plant Equivalent GHG usage 4.2 MW Wind Energy emission Embracing a low carbon future >> Reduction in water consumption by 12,000 KL per annum >> Zero Liquid Discharge across our major plants (ZLD) *as of March 31st, 2023 21 NATC
Slide 23: Financials
Financials
Slide 24: Performance Over the Years
Performance Over the Years INR Million FY20 FY21 FY22 FY23 FY24 Total Revenue 20,224 21,557 20,438 28,117 41,269 EBITDA* 6,900 7,098 3,625 10,402 18,795 EBITDA Margin* (%) 34.1% 32.9% 17.7% 37.0% 48.6% Profit before tax (PBT) 5,687 5,796 2,022 8,619 16,735 Profit after tax (PAT) 4,608 4,409 1,700 7,
Slide 25: Q4FY24 – Quarterly Performance
Q4FY24 – Quarterly Performance Revenue Breakup (INR mn) Revenue Breakup (%) – Q4FY24 4% 5% Revenue Division Q4FY24 Q4FY23 Q3FY24 FY24 FY23 5% API Revenue 500 728 463 2,492 2,103 Formulation Formulation – Exports (incl profit share, license income, export service income & 9,549 7,092 6,056 32,369 20,
Slide 26: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Q4FY24 Q4FY23 Q3FY24 FY24 FY23 Total Revenue 11,103 9,269 7,956 41,269 28,117 Total Expenses (before finance cost and depreciation) 5,710 5,588 4,905 22474 17,715 Earnings before interest, tax, depreciation and amortization 5
Slide 27: Consolidated Balance Sheet
Consolidated Balance Sheet Assets March 31st 2024 March 31st 2023 Liabilities March 31st 2024 March 31st 2023 Property , plant and equipment 22,977 22,391 Equity Equity share capital 358 365 Capital work -in-progress 1,373 643 Other equity 58,173 48,373 Goodwill 560 552 Total Equity 58,531 48,738 Ot
Slide 28: Annexure
Annexure
Slide 29: Capital Market Data – March 31st, 2024
Capital Market Data – March 31st, 2024 Shareholding pattern Top Marquee Shareholders Shareholder % Shareholding Life Insurance Corporation of India 3.9 24.49% Mirae Mutual Fund 2.8 Belgrave Investment Fund 1.9 Kotak Mahindra Life Insurance 0.9 HDFC Life Insurance 0.8 49.69% Market data (31st March 2
Slide 30: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546564 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma
Natco Pharma — B&K Securities Annual Investor Conference 2024 on 6ix